Monitoring Side Effects During VIP Regimen Infusion
During VIP (Vincristine, Ifosfamide, Cisplatin) infusion, you must monitor vital signs continuously, assess for infusion reactions immediately, check renal function and electrolytes before each cycle, and observe the infusion site closely for extravasation.
Pre-Infusion Baseline Assessment
Before initiating each VIP cycle, obtain:
- Complete blood count with differential (neutrophils, platelets, hemoglobin)
- Renal function panel: serum creatinine, BUN, creatinine clearance 1
- Electrolytes: magnesium, sodium, potassium, calcium 1
- Urinalysis to screen for microscopic hematuria (>10 RBCs per high power field) 2
- Neurologic examination for baseline peripheral neuropathy assessment 1
Critical threshold: Do not administer if neutrophils <500/mL, platelets <100,000/mL, or microscopic hematuria is present 3, 2.
During Infusion Monitoring
Immediate Infusion Reaction Surveillance
Monitor continuously for anaphylactic-like reactions, which can occur within minutes, particularly with cisplatin in previously exposed patients 1:
- Vital signs every 15 minutes during the first hour, then every 30 minutes
- Watch for: flushing, urticaria, bronchospasm, hypotension, tachycardia
- Have emergency medications immediately available: epinephrine 0.2-0.5 mg IM, diphenhydramine 50 mg IV, ranitidine 50 mg IV, corticosteroids 4
If the patient reports feeling "odd," uncomfortable, or has urge to urinate/defecate, stop the infusion immediately and measure blood pressure and pulse 4.
Extravasation Monitoring
Closely monitor the IV site continuously during cisplatin administration for signs of infiltration 1:
- Inspect for swelling, redness, pain at insertion site
- Assess for changes in infusion rate or resistance
- Stop infusion immediately if extravasation suspected
Hydration and Renal Protection
For cisplatin nephrotoxicity prevention 1:
- Administer adequate IV hydration before and after each cisplatin dose
- Monitor urine output (should maintain >100 mL/hour during infusion)
- Continue IV fluids for 5-7 days post-chemotherapy in outpatient setting if needed 5
For ifosfamide urotoxicity prevention 2:
- Mesna: 400 mg IV before day 1 ifosfamide, then 1,200 mg/day continuous IV infusion for 120 hours 3, 6
- Encourage vigorous oral or parenteral hydration 2
Post-Infusion Monitoring (Same Day)
- Assess for acute neurologic symptoms: somnolence, confusion, hallucinations (ifosfamide-related) 2
- Monitor for delayed nausea/vomiting requiring antiemetic adjustment
- Check vital signs before discharge
Inter-Cycle Monitoring (Between Treatments)
Weekly Blood Counts
Monitor CBC weekly between cycles 3:
- Watch for cumulative myelosuppression (most common with VIP) 3, 7
- Neutropenia is dose-limiting toxicity requiring potential G-CSF support 3
Renal Function Surveillance
- Repeat creatinine, BUN, electrolytes before each subsequent cycle 1
- Cisplatin causes cumulative nephrotoxicity—renal function must return to normal before next dose 1
- Monitor for electrolyte wasting (hypomagnesemia, hypokalemia, hypocalcemia) 1
Neurologic Assessment
Perform neurologic examination regularly before each cycle 1:
- Assess for peripheral neuropathy: paresthesias in stocking-glove distribution, loss of deep tendon reflexes, proprioception/vibratory sensation loss 1
- Vincristine contributes to cumulative neurotoxicity 8
- These neuropathies may be irreversible 1
Ototoxicity Screening
Audiometric testing should be performed:
- Prior to initiating therapy
- Before each subsequent cisplatin dose 1
- Cisplatin causes cumulative, potentially severe ototoxicity 1
Common Pitfalls to Avoid
- Do not reduce doses for neutropenia alone—use G-CSF prophylactically instead to maintain dose intensity 3
- Do not proceed with next cycle if fever present, neutrophils <500/mL, or platelets <100,000/mL at day 1 3
- Maximum delay: 3 days only for cycle postponement decisions 3
- Do not overlook microscopic hematuria—withhold ifosfamide until complete resolution 2
- Monitor infusion site continuously—extravasation has no specific treatment once it occurs 1
The VIP regimen requires intensive monitoring due to significant myelotoxicity, nephrotoxicity, neurotoxicity, and urotoxicity 3, 7. Adequate hydration, mesna uroprotection, and close surveillance are essential to prevent irreversible complications.